Michael Cusnir, MD:Selective internal radiation therapy is a technique that has been used for several years. This is something that I remember we started using when I was still in fellowship in the early 2000s. It entails giving a high dose of radiation internally to an organ, using that radiation as a treatment method for isolated areas of disease.
The advantage of using this in the liver, and the Yttrium-90 technology that has been developed since then, with a lot of different treatment modalities is twofold. We take advantage of the double circulation of the liver. The liver derives the nutrition from the portal vein, but the tumors derive their nutrition from the hepatic artery. That selectivity allows us to give certain treatments directly to the liver, like selective internal radiation. Using the technology of Yttrium-90 that has a wavelength of a beta emitter that is extremely short, that doesn’t cross into the surrounding tissues much more, allows you to be able to treat the liver in a selective fashion. We are able to selectively embolize the tumors and create an effect in the surrounding area that’s as close, in some cases, to being described as doing segmentectomy of the liver without damaging much of the healthy tissue.
This is a technology that has truly changed the way we approach patients who have nonresectable liver tumors that are able to undergo this technique safely, by having a good liver reserve.
Transcript edited for clarity.
Sotorasib/Panitumumab Combo Improves PFS in Refractory KRAS G12C+ mCRC
October 23rd 2023The multicenter, open-label, CodeBreaK 300 trial of sotorasib plus panitumumab showed consistent efficacy across key subgroups of patients with metastatic colorectal cancer harboring KRAS G12C mutations.
Read More
T-IELs Could Hold the Key for CRC Immunotherapy
October 10th 2023Researchers identified different functions of groups of intraepithelial T cells (T-IELs) throughout the gastrointestinal tract, which could help inform future immunological treatment for patients with colorectal cancer.
Read More
CAPOX Regimen Appears Noninferior to FOLFOX in CRC
October 8th 2023The treatment landscape for patients with resected stage III colon cancer has undergone a significant change, following publication of an International Development and Education Award presentation abstract in the August 2023 Journal of the National Comprehensive Cancer Network.
Read More